JB Pharma, one of the fastest growing pharmaceutical companies in India, has entered into an agreement with Glenmark Pharmaceuticals Ltd., to acquire the Entire Razel (Rosuvastatin) franchise for the India and Nepal region for a whopping Rs. 313.7 crores. With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this […]
The post JB Pharma to acquire the entire Razel (Rosuvastatin) franchise for Rs. 314 crores first appeared on World Pharma Today.This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here